{"_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwISPx9ELDA","founded_year":1886,"lastupdate":"2024-07-17T00:00:00.000Z","update_date":"2024-07-17T00:00:00.000Z","lastModified":"Jul 17, 2024","confidence_score":68,"active":1,"confidence_score_reason":"product stage, sector, founding month, business model, video or image, funding rounds, markets, not claimed","urlname":"johnson-johnson","minimal_profile":null,"status":"Public","fullstatus":"Public on NYSE on Jan, 1978;","acquired":0,"description_edited":1,"tag_line_edited":0,"phone":null,"registrar":null,"biverification":"Jenny Sotnik-Talisman","recentupdates":[{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:21:40.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:45:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:27.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:49:35.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:19:01.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:59:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:37.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:19:55.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:59:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:27.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:10:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:10:55.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 08:56:40.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 08:56:40.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:23:26.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 08:45:30.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-09 13:02:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-07-11 10:01:56.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:23:05.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:23:05.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:21:20.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2018-02-26 09:10:33.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2017-11-28 05:41:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2017-11-28 05:41:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"ngolczar@gmail.com","source":"Manual","datetime":"2017-11-28 05:41:05.000000","last_name":"Golczar","first_name":"Natalia"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-14 11:23:27.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2017-11-14 11:24:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"lena.rogovina@gmail.com","source":"Manual","datetime":"2019-02-04 12:19:09.000000","last_name":"Rogovina","first_name":"Lena"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-12-26 14:02:47.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-06-20 06:24:56.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:12:26.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:11:09.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:11:09.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:11:09.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:11:09.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2017-01-19 15:14:36.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-12-22 08:35:23.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-06-09 10:26:55.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-06-09 10:26:55.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-06-09 10:26:55.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2016-06-09 10:26:59.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:58:12.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:36:20.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:33:31.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:35:34.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:37:42.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:00:00.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:34:06.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:03:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:35:39.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:35:38.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:24:58.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 11:24:58.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:35:40.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 13:03:51.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-02 09:58:27.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:35:41.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:36:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:09:08.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:54:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:32:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:32:28.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:20:29.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 15:51:15.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:52:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:52:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 10:52:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:13:18.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:13:18.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:13:18.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2016-06-01 12:13:18.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 15:01:25.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:37:05.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:46:59.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-11-25 14:11:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-11-25 14:11:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"michalseror@gmail.com","source":"Manual","datetime":"2021-01-11 09:07:36.000000","last_name":"Seror","first_name":"Michal"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:37:46.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:27:07.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-31 16:51:46.000000","last_name":"McCandless","first_name":"Katie"},{"email":"yanina.wain@gmail.com","source":"Manual","datetime":"2019-10-14 19:48:50.000000","last_name":"Wainscheinker","first_name":"Yanina"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:25:10.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 16:27:59.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 16:27:59.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 16:27:59.000000","last_name":"McCandless","first_name":"Katie"},{"email":"katie.mccandless@gmail.com","source":"Manual","datetime":"2019-03-20 16:27:59.000000","last_name":"McCandless","first_name":"Katie"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 15:01:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:45:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:33:47.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-08-25 15:13:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2019-08-25 15:13:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:26:43.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:24:23.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:24:23.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:39:04.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 15:15:27.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:46:53.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:38:01.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:38:19.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"genys30@yahoo.com","source":"Manual","datetime":"2019-06-18 13:57:00.000000","last_name":"Sotnik-Talisman","first_name":"Jenny"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:37:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maorperlov@gmail.com","source":"Manual","datetime":"2020-05-07 14:37:38.000000","last_name":"Perlov","first_name":"Maor"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:29:09.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"yamila.urwicz@gmail.com","source":"Manual","datetime":"2019-03-14 13:30:59.000000","last_name":"Silbert","first_name":"Yamila"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2025-02-06 12:41:53.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:55:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:01:04.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:49.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-22 06:33:51.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:01:04.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:22:42.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:41:33.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-08-07 05:56:02.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:43:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:26.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:10:10.000000","last_name":"Levin","first_name":"Eran"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:51:16.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:22:11.000000","last_name":"Perlov","first_name":"Maor"},{"email":"eranl@sncentral.org","source":"Automatic","datetime":"2024-12-05 14:59:43.000000","last_name":"Levin","first_name":"Eran"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:22:42.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2024-07-17 13:55:43.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:45:24.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-10-18 18:56:19.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-03-14 19:44:48.000000","last_name":"Perlov","first_name":"Maor"},{"email":"maor.perlov@sncentral.org","source":"Manual","datetime":"2023-08-09 13:17:37.000000","last_name":"Perlov","first_name":"Maor"}],"sectorverify":null,"biverify":{"id":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAgMHXnNsIDA","fullname":"Jenny Sotnik-Talisman"},"biverifydate":"2020-05-07T00:00:00.000Z","crunchbaseid":"johnson-johnson","lastupdator":"Maor Perlov","lastupdator_email":"maor.perlov@sncentral.org","creator":"Yamila Silbert","creator_email":"yamila.urwicz@gmail.com","createdate":"2016-06-01T00:00:00.000Z","lastupdatedate":"2024-07-17","hide_reason":null,"hide_reason_data":null,"logokey":"$ZGZLV7DUlFkgUtW3RRol27Vr6RIBnPlja5TeXVQC7G3Ey1ZR0rrMIS.jpeg","name":"Johnson & Johnson","israeliacquisitions":2,"forbesranking":40,"investmentarm":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwITBs4MKDA","investmentarmname":"Johnson & Johnson Innovation","hubname":"FutuRx","acquired_amount":null,"acquired_by":null,"acquired_country":null,"acquired_month":null,"acquired_year":null,"type":"Multinational","formernames":[],"alternativenames":["JNJ","J&J","ethicon"],"country":"United States","inisraelsince":"9/1997","inisraelsincemonth":"9","isisraeli":0,"marketcapital":455043565915,"marketcapitaldate":"2025-11-01T14:08:15.000Z","oneliner":"Healthcare","website":"http://www.jnj.com/","employees":"201-500","employees_exact":314,"employees_overall":"50,000+","employees_overall_exact":129647,"sociallinks":{"twitter":"https://twitter.com/jnjinnovation","youtube":"https://www.youtube.com/user/JNJhealth","facebook":"https://www.facebook.com/jnj","linkedin":"https://www.linkedin.com/company/1207","instagram":""},"social":["https://www.youtube.com/user/JNJhealth","https://twitter.com/jnjinnovation","https://www.linkedin.com/company/1207","https://www.facebook.com/jnj"],"flattenedsociallinks":"https://www.youtube.com/user/JNJhealth|https://twitter.com/jnjinnovation|https://www.linkedin.com/company/1207|https://www.facebook.com/jnj","apps":{"appstore":"","googleplay":""},"investmentstage":[],"about":"Johnson & Johnson Inc engages in the research and development, manufacture, and sale of a range of products in the healthcare field. The company's segments include consumer, pharmaceutical, and medical devices. The company's primary focus is on products related to human health and wellbeing.\n\nIn Israel, Johnson & Johnson has four sub-companies. The company's operations in Israel span research and development, as well as commercial activities in the healthcare sector.\n","founded":"1886","team":[{"name":"Esther Rajchenbach-Beeri","email":"","phone":"","gender":"Female","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4K7ytN4KDA","bounced":false,"claimed":0,"founder":0,"urlname":"esther-rajchenbach-beeri","visible":1,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgnqjryAsM","position":"Head of HR","last_name":"Rajchenbach-Beeri","claimtoken":"d8cc85d234acf12a94267bd8b91f8ba08ae298bd4c07630a7a90146609a67862","first_name":"Esther","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/esther-rajchenbach-beeri-9051b51/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"ER","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Oron Agam","email":"oagam@its.jnj.com","phone":"","gender":"Male","userid":"aWyItEPfBaW4Zic6X9Hsn8207Q2h3p1CdhcQif44R0YS0j5YUHdPqu","bounced":false,"claimed":null,"founder":0,"urlname":"oron-agam","visible":1,"memberid":"3v5lrBXoEA2B8jxO1wAIfG5MUn118BdiotNp5A8LazyQQtvmxI2sSd","position":"General Manager Johnson & Johnson Medical Israel","last_name":"Agam","claimtoken":null,"first_name":"Oron","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/oron-agam-a46b0112/","unsubscribed":false,"is_activeuser":0,"additionalemail":"","claimedemaildate":null,"initials":"OA","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"none","teammembertagcontent":"","channelId":"","visibilityClassName":"","visibilityTooltip":""},{"name":"Erez Ilan","email":"eilan@its.jnj.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICA4IiZ2NELDA","bounced":false,"claimed":0,"founder":0,"urlname":"erez-ilan","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgIDgyNHtjwkM","position":"Senior Manager at Omrix R&D ","last_name":"Ilan","claimtoken":"2d3441bd346e7ec6c7f27a48c47a711cff6ca4c4f39c7d50fb568bd311d56f5c","first_name":"Erez","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/erezilan","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"EI","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"},{"name":"Uri Yaron","email":"uyaron1@its.jnj.com","phone":"","gender":"Male","userid":"agxzfmlsbGlzdHNpdGVyFQsSCE5ld19Vc2VyGICAoJHE6b8JDA","bounced":false,"claimed":0,"founder":0,"urlname":"uri-yaron-2","visible":0,"memberid":"agxzfmlsbGlzdHNpdGVyFwsSCk5ld19NZW1iZXIYgICg4a3BjAsM","position":"Worldwide President, Biosense Webster ","last_name":"Yaron","claimtoken":"603371d97d4b39146ba09345ab654cbd6f10c53adffc1d7bf8c446bd767b55ab","first_name":"Uri","picturekey":null,"claimeddate":null,"linkedinurl":"https://www.linkedin.com/in/uri-yaron-a0234/","unsubscribed":false,"is_activeuser":1,"additionalemail":"","claimedemaildate":null,"initials":"UY","pictureurl":"/assets/empty-state.svg","linkedin-display":"flex","teammembertagclass":"connect","teammembertagcontent":"Connect","channelId":"","visibilityClassName":"private-visibility","visibilityTooltip":"tooltip tooltip-html-content='<style>\n    .visibility-tooltip-container {\n        display: flex;\n        column-gap: 0.8rem;\n        padding: 0.8rem 1rem;\n        align-items: center;\n    } \n\n    .visibility-tooltip-container text {\n        font-size: 1.4rem;\n        text-transform: capitalize;\n        font-weight: 500;\n    }\n</style>\n\n<div class=\"visibility-tooltip-container\">\n    <img height=\"20\" width=\"20\" style=\"display: flex\" src=\"/assets/private-visibility.svg\"/>\n    <img height=\"20\" width=\"20\" style=\"display: none\" src=\"/assets/internal-visibility.svg\"/>\n    <text>private</text>\n</div>'"}],"portfolio":[{"name":"Biosense Webster","hidden":false,"raised":"Undisclosed","founded":"1993","fullurl":"/company_page/biosense-webster","logokey":"$eqVfeKBye9VzuBBd6GSDnEvVKaHzrvjKjKYtX8XdYGeYlWaGSXY1O8","urlname":"biosense-webster","employees":"500+","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7R9dcIDA","description":"Diagnosis and Treatment of Cardiac Arrhythmias","fundingstage":"Acquired","businessmodel":"B2B, B2C","raisedNumber":0,"logourl":"https://storage.googleapis.com/clean-finder-353810/$eqVfeKBye9VzuBBd6GSDnEvVKaHzrvjKjKYtX8XdYGeYlWaGSXY1O8","style":"","hiddenCompanyTooltip":""},{"name":"Omrix Biopharmaceuticals","hidden":false,"raised":"$4.84M","founded":"1995","fullurl":"/company_page/omrix-biopharmaceuticals","logokey":"$DdtuveFOAg8pjr2tfJ0iIfUIPz5cCPNSFQjATSfQmGTK7dvVryIhyj","urlname":"omrix-biopharmaceuticals","employees":"201-500","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN7Z47ALDA","description":"Human Plasma Derived Products","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":4840000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$DdtuveFOAg8pjr2tfJ0iIfUIPz5cCPNSFQjATSfQmGTK7dvVryIhyj","style":"","hiddenCompanyTooltip":""},{"name":"V-Wave","hidden":false,"raised":"$132.5M","founded":"2009","fullurl":"/company_page/v-wave","logokey":"$zQwUDEQr8hGVlc5mjaamPLi24N5i1KRl6uySQXKlnrYzlVQ5ueYido","urlname":"v-wave","employees":"11-50","company_id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgN6A-4wLDA","description":"Miniature Shunt for Treating Congestive Heart Failure","fundingstage":"Acquired","businessmodel":"B2B","raisedNumber":132500000,"logourl":"https://storage.googleapis.com/clean-finder-353810/$zQwUDEQr8hGVlc5mjaamPLi24N5i1KRl6uySQXKlnrYzlVQ5ueYido","style":"","hiddenCompanyTooltip":""}],"exits":[],"mediagallery":[],"affiliatedOrganizations":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKP2oZIKDA","name":"FutuRx","type":"Investor","hidden":false,"fullurl":"/investor_page/futurx","logokey":"$XxQiFrU4R30LKDcmXaXZVedqfornovhC31j8y0EG4TthCyoN21hBrd","logourl":"https://storage.googleapis.com/clean-finder-353810/$XxQiFrU4R30LKDcmXaXZVedqfornovhC31j8y0EG4TthCyoN21hBrd","onClick":"","visibilityClassName":"","visibilityTooltip":""},{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwITBs4MKDA","name":"Johnson & Johnson Innovation","type":"Investor","hidden":false,"fullurl":"/investor_page/johnson-johnson-development-corporation","logokey":"$4EccGeA7CnODtuJfuXZHm6rgAKVHb8UpRtVyqZSCmQ4mKkYeHPeURP","logourl":"https://storage.googleapis.com/clean-finder-353810/$4EccGeA7CnODtuJfuXZHm6rgAKVHb8UpRtVyqZSCmQ4mKkYeHPeURP","onClick":"","visibilityClassName":"","visibilityTooltip":""}],"address":{"israeli":[{"id":"5545a253-1dae-45fd-9af2-1427d5ddef60","city":"Shefayim","type":["Sales"],"address":"Shefayim, Israel","placeid":null,"notactive":0,"openeddate":"1996-08-01","registrarid":"512363904","firstrdcenter":0,"registrarname":"J-C Health Care Ltd"},{"id":"9bf066e5-43fc-4850-9bd0-e50f9a7865cb","city":"Yokne'am Illit","type":["R&D"],"address":"Yokne'am Illit, Israel","placeid":null,"notactive":0,"openeddate":"1997-09-01","registrarid":"511859134","firstrdcenter":0,"registrarname":"Biosense Webster"}],"officesabroad":[{"id":"FX5KNOziIcNW8u1EaTHadcqnHPldLsa04RK0wEuCeTlzV77OWUva1l","city":null,"address":"New Jersey, USA","country":"United States","placeid":"ChIJn0AAnpX7wIkRjW0_-Ad70iw"}]},"headquarter_address":"NJ, United States","news":[{"id":"4F7e2Y7sUWQhh0XpcUDvVrTtcyFskjm8JJ5FP8pgFtnAGq1lJqnLOu","date":"Oct 21, 2025","link":"https://finance.yahoo.com/news/inspira-appoints-former-johnson-johnson-194000626.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Management Changes","round":null,"company":"Inspira Technologies","layoffs":null,"summary":"Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from Johnson & Johnson and other med-tech firms. Sivan Matza joins the board as an independent director, leveraging her background in global finance and regulation. These appointments aim to enhance Inspiras sales strategy and hospital adoption initiatives, positioning the company for its next phase of growth. The company also acknowledged the contributions of Limor Rosen, who is stepping down from the board.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["leadership","governance","sales","expansion","healthcare"],"date_of_event":"October 21, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"cHxOYdEXVmtZvSt8HO2wKEF8MzogbVPYkRIDj0hg7snwLDSc2X0AKG","news_summary":"Inspira Appoints Former Johnson & Johnson Senior Business Manager as VP of Global Sales and New Board Member from a Leading International Investment Firm","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"266yZjtGy9j7tKluhANsCieqkkKlyKxfAhAo7sjC93m4EdF3u7mEJo","date":"Oct 21, 2025","link":"https://finance.yahoo.com/news/inspira-appoints-former-johnson-johnson-130500785.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"management changes","round":null,"company":"Inspira Technologies","layoffs":null,"summary":"Inspira Technologies announced key leadership changes to bolster its global commercialization and governance efforts. Mike Hershkovitz has been appointed as Vice President of Global Sales, bringing extensive experience from the healthcare sector, including roles at Johnson & Johnson. Sivan Matza joins the board as an independent director, succeeding Limor Rosen. Matzas background in international finance and regulation is expected to enhance Inspiras governance framework. These appointments are strategic moves to accelerate Inspiras commercial expansion and adoption of its technologies in hospitals worldwide. The company expressed gratitude to Limor Rosen for her contributions.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["leadership","governance","expansion","sales","healthcare"],"date_of_event":"October 21, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Management Changes"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Management Changes","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"BnPFFTijzyLdu2y72JHtaLha0AsGEOvCfH9aIbq2LpkPIhVLBJfHcA","news_summary":"Inspira Appoints Former Johnson & Johnson Executive as VP of Global Sales and New Board Member from a Leading International Investment Firm","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"18FxEZbf4bk1ZgtMAfJ6SmvOcFcGEZaVaC4ErLDQlVyiT5Njg1k9Qg","date":"Oct 21, 2025","link":"https://finance.yahoo.com/news/johnson-johnson-targets-accelerated-growth-131300720.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"outlook","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson (J&J) discussed its optimistic outlook for 2026 during its third-quarter earnings call on October 14. The company expects top-line growth of over 5%, surpassing the consensus estimate of 4.6%. J&J anticipates similar growth in EPS, projecting it to be 5 cents higher than the consensus of $11.39 per share. Despite the loss of exclusivity for Stelara, J&J expects growth in its Innovative Medicine and MedTech segments, driven by key products and new launches. The MedTech segment is expected to benefit from increased adoption of new products and a focus on high-growth markets. J&Js guidance reflects a strategic shift towards innovation-led growth.","partners":["Amgen","Teva Pharmaceutical Industries","Samsung Bioepis/Sandoz"],"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["earnings","growth","biosimilars","innovation","MedTech"],"date_of_event":"October 14, 2023","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"asI9Q5biwQtdl9q6wmBRFh1veXJhivf2qm4d4POPnhXZrUeEp1MdZD","news_summary":"Johnson & Johnson Targets Accelerated Growth Across Segments in 2026","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"EBb89Ge0J3Q9tlUeWGoFIgCNltaxw860rLAV7BqvRxUFZnSppv5aCP","date":"Oct 14, 2025","link":"https://finance.yahoo.com/news/jnj-beats-q3-earnings-ups-160000522.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings, sales","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson reported strong third-quarter 2025 earnings, with earnings per share of $2.80, surpassing the Zacks Consensus Estimate of $2.77. This marks a 15.7% increase from the previous year. The companys sales reached $24.0 billion, exceeding expectations and reflecting a 6.8% rise from the prior year. The growth was driven by increased sales in the Innovative Medicines segment, particularly from key products like Darzalex, Tremfya, and Erleada. Despite some challenges from generic competition affecting drugs like Imbruvica, the overall performance was robust. The companys international sales also showed significant growth, contributing to the positive outlook.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["earnings","sales","growth","competition","drugs"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"FDA approved","AI technology developing/using":"not mentioned","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Z6dcLDotl9Y888E002ek6NqSzRYUnttHVUXTFH06QnHzCwHAPCpiEh","news_summary":"JNJ Beats on Q3 Earnings, Ups Sales View, to Spin-off Orthopaedics Unit","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"AJel7AKOAwIJxlMFehAYxKpdaaxcUO0BY3ltjggj8kYBg2i8I79qew","date":"Oct 10, 2025","link":"https://finance.yahoo.com/news/buying-j-j-stock-ahead-161000544.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson is set to report its third-quarter 2025 earnings on October 14, with expectations of a positive earnings surprise. The companys performance has been strong, consistently exceeding earnings expectations over the past four quarters. Key products such as Darzalex, Tremfya, and Erleada are expected to drive sales growth, while new drugs like Carvykti and Tecvayli are contributing to top-line growth. However, the Innovative Medicines segment faces challenges due to the launch of biosimilar versions of Stelara, impacting growth negatively. Despite this, the overall outlook remains positive, with a projected earnings beat.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["earnings","sales","biosimilars","growth","competition"],"date_of_event":"October 14, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"7qyanTBqsVYyMSt44uNlMzK9DU6DMFKfFwFd7SapAq5VjByj7jhjvB","news_summary":"Buying J&J Stock Ahead of Q3 Earnings? Here's What You Should Know","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"Heh0l2q3JhP3baKWz1GjvV80tLe512YvrhzDziECd4ichWhmqblZe9","date":"Oct 6, 2025","link":"https://finance.yahoo.com/news/zacks-approach-beat-markets-amneal-120700906.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Amneal Pharmaceuticals, Inc.","layoffs":null,"summary":"The U.S. stock market saw a strong performance last week, with major indices showing gains despite a partial government shutdown. Investor optimism was fueled by innovations in Artificial Intelligence and hopes for interest rate cuts by the Federal Reserve. However, the shutdown has caused uncertainties due to delays in economic data releases. The Conference Boards Consumer Confidence Index fell, indicating concerns over inflation and a weakening job market. Amid these conditions, Zacks Research has provided guidance to investors, highlighting the performance of stocks like Amneal Pharmaceuticals, Inc., which gained 29.9% since being upgraded to a Zacks Rank #2. The article underscores the importance of strategic investment decisions in uncertain market conditions.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["stock market","AI innovations","interest rates","consumer confidence","labor market"],"date_of_event":"Last week","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"i3NNSdk4kXLyJoEICb3LLTU1WVGgkmW7DHuOQdb2ZBHyt9hwtp74s5","news_summary":"Take the Zacks Approach to Beat the Markets: Amneal Pharmaceuticals, Leidos & Vishay Precision in Focus","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"EOTIBVj2smeGlIefHNPYS0XnYvgQI4g6DtYUpEEkloGKaBcZ9c4iab","date":"Sep 22, 2025","link":"https://finance.yahoo.com/news/j-j-adds-63b-market-131600655.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson (J&J) has experienced a significant stock price increase, with shares up 17.7% over the past three months, adding nearly $63 billion in market capitalization. The companys Innovative Medicine unit is showing growth, with sales rising 2.4% in the first half of 2025. J&J expects continued growth driven by key products and new drugs. The MedTech segment also saw sales growth, driven by acquisitions and new product adoption. J&Js oncology sales are projected to exceed $50 billion by 2030. Recent FDA approvals for drugs like Inlexzo and acquisitions such as Intra-Cellular Therapies are contributing to J&Js positive outlook.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":10,"key_topics":["stock","oncology","medtech","acquisition","FDA approval"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":"Intra-Cellular Therapies","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Acquisition","FDA approved/pending approval"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Acquisition  #FDA approved/pending approval","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"tXbOwySXNpkftCgd4OTE4h18tNGVOtXO0T7cw7BtaFG1XS4SP0rn6W","news_summary":"J&J Adds $63B in Market Cap in 3 Months: Time to Buy the Stock?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"y54DOn37jtImtQ4g3K68C3s9E3K1o2Xo1zJO1OEgcBF8IpqLRpKgYY","date":"Sep 18, 2025","link":"https://finance.yahoo.com/news/j-j-expects-innovative-medicines-153000278.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["patent loss","biosimilars"],"round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnsons immunology drug, Stelara, lost its patent exclusivity in the United States in 2025, leading to the launch of several biosimilar versions by companies like Amgen, Teva Pharmaceutical Industries/Alvotech, and Samsung Bioepis/Sandoz. This has significantly eroded Stelaras sales, which declined by 42.7% in the second quarter of 2025, impacting J&Js sales and profits. Despite this, J&J anticipates growth in its Innovative Medicine segment, driven by other key products and new drugs. The company expects to generate over $57 billion in sales in this segment in 2025, maintaining levels similar to 2024.","partners":["Amgen","Teva Pharmaceutical Industries/Alvotech","Samsung Bioepis/Sandoz"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Stelara","biosimilars","patent","sales","growth"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"UJtGBb1JZWx9EY52InYn1XJzZm0V47NqdUYBecOZemWZeD3nIZY94w","news_summary":"J&J Expects Innovative Medicines Growth Despite Stelara LOE: Here's Why","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"uPbFmx3aAz8VTw7ganbjJLU9u4XOgYSVGbpNpbTFnM0YUKV5Sb1alF","date":"Aug 28, 2025","link":"https://finance.yahoo.com/news/commentary-trumps-trade-war-is-hurting-most-sectors-of-the-economy-191706763.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"tariffs","round":null,"company":"General Motors","layoffs":null,"summary":"The article discusses the negative impact of President Trumps tariffs on various sectors of the US economy, particularly highlighting the effects on companies within the S&P 500 index. It notes that tariffs have significantly increased costs for businesses, leading to reduced profits and price hikes. General Motors, for example, reported a $1.1 billion hit to profits in the second quarter due to tariffs. Other companies like Ford, Home Depot, and Walmart also face similar challenges, with increased costs and reduced profit margins. The article emphasizes the widespread economic damage caused by the tariffs, affecting both businesses and consumers.","partners":null,"customers":["General Motors","Ford","Deckers Outdoor","Home Depot","TJX","Walmart","Keurig Dr. Pepper","Kraft Heinz","SolarEdge","Sunrun","Baker Hughes"],"eventType":null,"investors":null,"confidence":9,"key_topics":["tariffs","profits","price hikes","trade war","earnings"],"date_of_event":"second quarter","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Bn6fZnu6PasC9bdzWYRc1YZXtchos3UqOdllcrEYb37sYHnH5xi14R","news_summary":"Commentary: Trump’s trade war is hurting most sectors of the economy","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"IzmLw5fyyhGwLL7owB5rnGlrH1RxRKPyWpXt3SOkPl9uZA98MWTsRH","date":"Aug 25, 2025","link":"https://finance.yahoo.com/news/j-j-stock-trading-above-123900252.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"stock performance","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson (J&J) has been experiencing a positive stock performance, with its stock trading above the 50-day and 200-day simple moving averages since mid-June 2025. This bullish trend, known as a golden cross, suggests potential for continued upward momentum. J&Js strengths lie in its diversified business model, operating in both medical devices and pharmaceuticals. The company separated its Consumer Health business into Kenvue, allowing it to focus on core areas. Despite challenges like the loss of exclusivity for Stelara, J&Js Innovative Medicine unit is showing growth, with expectations of significant sales in 2025 and beyond. The company anticipates oncology sales to exceed $50 billion by 2030.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":9,"key_topics":["golden cross","stock performance","diversification","R&D budget","Innovative Medicine"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"IpDroHUpoU3rwIbvugmTgiRI1JrIOpCVbWwIPH9EJwWj5t2yl3AcxZ","news_summary":"J&J Stock Trading Above 200 & 50 Day SMA for 2 Months: Time to Buy?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"RGMZpkZWGFE7irF6quSiWNxLpCVoo8i4nKZDQbk8FRoQOJOPjPhwtj","date":"Aug 21, 2025","link":"https://finance.yahoo.com/news/latest-global-biologics-biosimilars-market-163000561.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"market research","round":null,"company":"Custom Market Insights","layoffs":null,"summary":"The article discusses a market research report by Custom Market Insights on the global Biologics and Biosimilars market. The report highlights the markets growth potential, with an expected increase from USD 478.83 billion in 2024 to USD 1,320.19 billion by 2034, at a CAGR of 10.42%. The growth is driven by the rising incidence of chronic diseases like cancer and diabetes, necessitating long-term treatments. The expiration of patents for major biologics has opened the market for biosimilars, offering cost-effective alternatives. The report also emphasizes advancements in biomanufacturing technologies that enhance production efficiency.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["Biologics","Biosimilars","Market Growth","Chronic Diseases","Biomanufacturing"],"date_of_event":"August 21, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"Rj8uPimRuEKNyjDHu7UgknJlHBacU12cYcM1uYsPnE4863g9E2vnTI","news_summary":"[Latest] Global Biologics and Biosimilars Market Size/Share Worth USD 1,320.19 Billion by 2034 at a 10.42% CAGR: Custom Market Insights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"m7229KF8of4AufjdBchkqmAb5MpU92xSTCvs2vGYbj6DPXJUbQCCbc","date":"Aug 21, 2025","link":"https://finance.yahoo.com/news/us-eu-trade-deal-impacts-on-pharma-industry-more-manageable-than-expected-153242223.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"trade deal","round":null,"company":"Pfizer","layoffs":null,"summary":"The recent trade deal between the US and the EU, which sets a 15% cap on import tariffs for pharmaceutical goods, has been positively received by the pharmaceutical industry. Stocks of major pharmaceutical companies like Pfizer, Eli Lilly, and Johnson & Johnson saw a slight increase following the announcement. The deal aims to equalize US drug costs with those in the EU by applying the higher of either the US MFN tariff rate or a 15% tariff on EU-manufactured drugs. Additionally, the US will enforce MFN pricing on generics and chemical precursors starting September 1. This is seen as a manageable change, with limited financial impact on the industry.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["tariffs","pharmaceuticals","trade deal","drug prices","generics"],"date_of_event":"August 21, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":null,"AI technology developing/using":null,"entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"g3G0gMwtWNFlSnrJ1ySUDEJCz2k7BZb6F0fCFnkSOo0zR4gjRKQoxK","news_summary":"US-EU trade deal impacts on pharma industry more 'manageable' than expected","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"xbKr5yf1umIOh22kANjgdxAwCPQbgP4TamfyM8Ek15fwT3i5z7ywar","date":"Jul 31, 2025","link":"https://finance.yahoo.com/news/teva-q2-earnings-beat-revenues-163800069.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"earnings report","round":null,"company":"Teva Pharmaceutical Industries","layoffs":null,"summary":"Teva Pharmaceutical Industries reported second-quarter 2025 adjusted earnings of 66 cents per share, surpassing the Zacks Consensus Estimate of 63 cents. However, revenues of $4.18 billion missed the estimate of $4.28 billion, remaining flat year over year. The revenue growth was hindered by lower generic drug sales, despite increased sales of branded drugs like Austedo, Ajovy, and Uzedy. Tevas exit from Japan contributed to the decline in generic sales. The company launched new biosimilars, Simlandi and Selarsdi, in partnership with Alvotech, and Epysqli with Samsung Bioepis. Despite these efforts, Tevas shares have decreased by 23.6% this year, compared to the industrys 9.8% decline.","partners":["Alvotech","Samsung Bioepis"],"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["earnings","revenues","biosimilars","partnerships","sales"],"date_of_event":"2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Product Stage","Partners","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"not mentioned","structuredIssuesShow":"#Product Stage  #Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"EsprlaJQ84I4c3a8ffu2c3pMlzuKsMAIc21yQdJCm83oqjnp6tBQyC","news_summary":"TEVA Q2 Earnings Beat, Revenues Miss on Lower Generics Sales","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"PArUAhE41OxxoVFINC98bbaEzFzdsiaYwcXU7IrbvmIvIyYFouNbLz","date":"Jul 21, 2025","link":"https://finance.yahoo.com/news/j-j-stock-portfolio-q2-133600021.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":["earnings","guidance"],"round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson (J&J) reported strong second-quarter 2025 results, surpassing expectations in both revenue and earnings. Despite the loss of exclusivity for Stelara, J&Js Innovative Medicines unit and MedTech segment performed well, driven by strong sales of key drugs and new products. The company raised its sales and EPS guidance for the year, reflecting strong operational performance and favorable currency impacts. J&Js shares rose over 6% following the earnings announcement. The companys diversified business model, with operations in both medical devices and pharmaceuticals, continues to be a significant strength. In 2023, J&J separated its Consumer Health business into a new company, Kenvue, allowing it to focus on its core areas.","partners":[],"customers":[],"eventType":null,"investors":[],"confidence":10,"key_topics":["earnings","guidance","MedTech","pharmaceuticals","diversification"],"date_of_event":"July 16, 2025","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":[],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":"using","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ScJaJgo9P93sXVQ4btxA5ccStWTuZhDOuzEWCmfgG6Uz36QQLltVM4","news_summary":"Should J&J Stock Be in Your Portfolio After Q2 Beat & Guidance Raise?","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"h88u2aiP3f0jPEOx7ffWukSLiwZfFxipTfbpnEDLRteTBV4B3vhvwK","date":"Jul 11, 2025","link":"https://finance.yahoo.com/news/teva-stock-more-20-three-123100922.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"growth","round":null,"company":"Teva Pharmaceutical Industries Limited","layoffs":null,"summary":"Teva Pharmaceutical Industries Limited has seen a 21.6% rise in its stock price over the past three months, driven by the successful launch of several biosimilars and high-value generics. The companys branded drugs, including Austedo, Uzedy, and Ajovy, are experiencing strong sales growth. Teva has implemented cost-cutting measures to improve operating profits and reduce debt. The company anticipates significant revenue growth from its branded products by 2030, with Austedo expected to generate over $2.5 billion annually by 2027. Teva has partnered with Sanofi to advance its anti-TL1A therapy, duvakitug, into phase III trials. The company continues to expand its market presence with new launches in Europe and international markets.","partners":["Sanofi"],"customers":["Novo Nordisk","Roche","AbbVie","J&J","Novartis","AstraZeneca"],"eventType":null,"investors":null,"confidence":9,"key_topics":["biosimilars","branded drugs","cost-cutting","market share","pipeline"],"date_of_event":"2023","product_stage":"released","investment_date":null,"acquired_company":null,"valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Partners","Customers"],"acquisition_amount":null,"FDA approved/pending approval":"pending approval","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Partners  #Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"dIIUwtYedgMcc4NXQyUZo9LoGmq3OFfdSXIpxvTB8LqNsFwWXtL3bk","news_summary":"TEVA Stock Up More than 20% in Three Months: Buy, Sell or Hold the Stock?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"RS7jKdQxoZxJit8NATJpcRq4ljbBwFXfKeHLaQKIYCmihY6gZr8nst","date":"Jun 23, 2025","link":"https://finance.yahoo.com/news/j-j-adds-more-15b-132200263.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"diversification","round":null,"company":"Johnson & Johnson","layoffs":null,"summary":"Johnson & Johnson (J&J) has seen a 4.4% rise in its stock over six months, adding over $15 billion to its market value. Despite challenges like slowing MedTech sales, loss of exclusivity for Stelara, and talc lawsuits, J&Js strengths lie in its diversified business model and strong Innovative Medicine unit. The company has separated its Consumer Health business into Kenvue, allowing it to focus on pharmaceuticals and medical devices. J&J anticipates significant growth in its Innovative Medicine segment, driven by key products and new drug launches, with expectations of over $57 billion in sales by 2025.","partners":null,"customers":null,"eventType":null,"investors":null,"confidence":9,"key_topics":["stock rise","drug exclusivity","talc lawsuits","new drugs","pipeline"],"date_of_event":"2023","product_stage":"released","investment_date":null,"acquired_company":"Kenvue","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Product Stage","Acquired-by"],"acquisition_amount":null,"FDA approved/pending approval":"approved","AI technology developing/using":null,"structuredIssuesShow":"#Product Stage  #Acquired-by","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"w0SF9UjgpAid1sm7mZcg6hONzaqjRNnvbdKbqWo5YVw5ZZR3RrQLSV","news_summary":"J&J Adds More Than $15B in Six Months: How to Play JNJ Stock?","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"U2jQNpxz3QhKQEvcoWSDRc5rmwyBovlTZof87VWPzN9PMrvgNSy1Uu","date":"May 5, 2024","link":"https://www.foxbusiness.com/lifestyle/pharma-giant-adds-israel-list-middle-east-markets-omission-raises-questions","source":"www.foxbusiness.com","visible":1,"analysis":{"tags":"Website Update","company":"Johnson & Johnson","layoffs":"N/A","summary":"Johnson & Johnson has added Israel to its list of global markets on its order management website, Customer Connect, after questions were raised about its absence. The website is a tool for the companys direct customers and distributors in North America, Latin America, Europe, Middle East, Africa, and Asia Pacific. The company clarified that the tool isnt used for all markets, and customers in markets not listed, including Israel, use a different method to order products. The company also condemned the Oct. 7 Hamas terrorist attack on Israel and donated $2 million to support humanitarian relief.","partners":"N/A","customers":"N/A","investors":"N/A","confidence":9,"key_topics":["Website Update","Israel","Customer Connect","Order Management","Antisemitism"],"date_of_event":"N/A","valuation_amount":"N/A","impact_on_company":"growth-positive","investment_amount":"N/A","structured_issues":["Customers"],"acquisition_amount":"N/A","structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"xXmsO6sjwUKpQNgMqvDmqr8GLwfkIJ2B89EGCOMgYqKphOUqzBwxmq","news_summary":"Pharma giant adds Israel to list of Middle East markets after omission raises questions","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"VY4LEzGg6H7QTj1TDtzmo01HwQIm3iojeNfqaU3cyY4TALZ43h699W","date":"Oct 21, 2023","link":"https://finance.yahoo.com/news/bank-bonds-cut-risk-draw-190000717.html","source":"finance.yahoo.com","visible":1,"analysis":{"tags":"Securitization, Regulatory Capital","company":"Banks","layoffs":"NA","summary":"Banks are reviving the sale of credit-linked notes, a type of synthetic securitization, ahead of new rules that will require them to hold more regulatory capital. The bonds are used by lenders to reduce the financial resources they have to retain against loans on their balance sheet. The revival comes as banks wait to hear the latest terms of forthcoming Basel III regulations. Analysts at JPMorgan Chase & Co. see the mortgage-related CLN market alone growing to about $60 billion in the US in five years time. Magnetar Capital and Ares Management Corp. are also buying the bonds, which can yield anything from high single digits to mid-double digits, depending on the underlying collateral.","partners":["Magnetar Capital","Ares Management Corp.","KKR & Co.","Blackstone Inc."],"customers":"NA","investors":["Magnetar Capital","Ares Management Corp.","KKR & Co.","Blackstone Inc."],"confidence":8,"key_topics":["Credit-Linked Notes","Regulatory Capital","Basel III Regulations","Investment","Risk Transfer"],"date_of_event":"NA","valuation_amount":"NA","impact_on_company":"growth-positive","investment_amount":"NA","structured_issues":["Investment","Partners"],"acquisition_amount":"NA","structuredIssuesShow":"#Investment  #Partners","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"c9XiLc9aK9R17XWPPgni66Lbwn3yFGpnwfnd59H5fOV1aJJz95SxOZ","news_summary":"Bank Bonds That Cut Risk Draw Ares and Blackstone: Credit Weekly","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"lHMnGPIauvC1X2q60PzIX1sleLjUd7qMo3vtatRpqPyUnVatePJbMV","date":"Oct 18, 2023","link":"https://finance.yahoo.com/news/j-j-weighs-third-bankruptcy-224147640.html","source":"finance.yahoo.com","visible":1,"analysis":{"entityGrowthIconPath":"none;"},"sentiment":null,"analysisId":"NKsnBSOOTcjUenHpQbu1ilXcKKg3vQf5rItSc0ReTrdSPsqvsmSqZd","news_summary":"J&J Weighs Third Bankruptcy Try to Settle Baby Powder Suits","analysisStructuredIssuesDisplay":"none","analysisImpactOnCompanyDisplay":"block"},{"id":"d9c396d5-688c-4f15-8142-c798444958e4","date":"Jun 18, 2019","link":"https://en.globes.co.il/en/article-jj-to-close-tel-hashomer-blood-bank-operations-1001290072","source":"en.globes.co.il","visible":1,"analysis":{"tags":"closing down operations","company":"Johnson & Johnson","layoffs":100,"summary":"Johnson & Johnson is closing down its blood bank at Sheba Medical Center in Israel, which it acquired through Omrix Biopharmaceuticals. The facility will operate on a limited format until 2021, when it will be shut down completely. This follows the closure of Johnson & Johnsons plant in Jerusalem last year. 100 employees will be laid off as a result of the blood bank closure. Johnson & Johnson acquired Omrix in 2008 for $348 million. The company develops blood plasma-based products for surgery. The state of Israel previously filed a lawsuit against Johnson & Johnson regarding intellectual property, which was settled in 2006. Johnson & Johnson is still active in Israel through its subsidiary Biosense Webster.","partners":null,"customers":null,"investors":null,"confidence":8,"key_topics":["Johnson & Johnson","closing down operations","blood bank","Omrix Biopharmaceuticals","Sheba Medical Center"],"date_of_event":"June 18, 2019","valuation_amount":null,"impact_on_company":"growth-negative","investment_amount":null,"structured_issues":["Layoffs"],"acquisition_amount":null,"structuredIssuesShow":"#Layoffs","entityGrowthIconPath":"url(/assets/circle-red.svg);"},"sentiment":"growth-negative","analysisId":"Tc8xAZgjcTOAxmHACvTtdADhR89Njp2hfTvMdT9S2GUf0WRlCmacuN","news_summary":"J&J to close Tel Hashomer blood bank operations","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"b43a069a-e5dc-404e-97fd-3201e3dbecef","date":"Jan 12, 2016","link":"http://www.globes.co.il/en/article-johnson-johnson-leads-28m-round-in-israels-v-wave-1001094711","source":"www.globes.co.il","visible":1,"analysis":{"tags":"Investment, Management Changes, Expand","company":"V-Wave","layoffs":"Not mentioned","summary":"Israeli startup V-Wave has raised $28 million in a funding round led by Johnson & Johnson Innovation - JJDC Inc., with participation from TriVentures, Pura Vida, BioStar Ventures, Eli and Nir Barkats BRM fund, Pontifax and Edwards Lifesciences. The funds will be used to support clinical evaluation and development, addition of senior management and manufacturing scale-up of V-Waves proprietary minimally invasive device for use in patients with chronic symptomatic heart failure. The company has already successfully implanted the device in 30 patients.","partners":"Not mentioned","customers":"Not mentioned","investors":["Johnson & Johnson Innovation - JJDC Inc.","TriVentures","Pura Vida","BioStar Ventures","Eli and Nir Barkats BRM fund","Pontifax","Edwards Lifesciences"],"confidence":9,"key_topics":["Fundraising","Heart Failure Device","Clinical Evaluation","Management Addition","Manufacturing Scale-up"],"date_of_event":"January 12, 2016","valuation_amount":"Not mentioned","impact_on_company":"growth-positive","investment_amount":"$28 million","structured_issues":["Investment","Management Changes","Expand"],"acquisition_amount":"Not mentioned","structuredIssuesShow":"#Investment  #Management Changes  #Expand","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"ZwrcDkc8Kn3XBMxyU610aVooIdPPt35iD9N65Tdfx6fw998q8yPoTQ","news_summary":"J&J leads $28m round in Israel's V-Wave","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"6bdb1155-84a4-4b13-a0a7-1cd36fcd2574","date":"Jan 9, 2014","link":"http://www.israel21c.org/johnson-johnson-to-establish-new-biotechnology-incubator-in-israel/","source":"www.israel21c.org","visible":1,"analysis":{"tags":"expansion, collaboration","company":"Johnson & Johnson Innovation","layoffs":null,"summary":"Johnson & Johnson Innovation is expanding its global incubator presence in Israel with a new biotechnology incubator. The company is collaborating with the Office of the Chief Scientist in Israel and other industry partners to set up the research and development center. The new incubator aims to support and advance new companies with funding and strategic advice. Partners involved in the project include Johnson & Johnson Development Corporation, Takeda Pharmaceutical, and OrbiMed Israel Partners. Johnson & Johnson Innovation has been announcing several new R&D collaborations worldwide to fuel entrepreneurship. The new Israeli incubator is expected to be operational in early 2014.","partners":"Office of the Chief Scientist in Israel, Johnson & Johnson Development Corporation, Takeda Pharmaceutical, OrbiMed Israel Partners","customers":null,"investors":null,"confidence":8,"key_topics":["biotechnology","incubator","collaboration","R&D","entrepreneurship"],"date_of_event":"early 2014","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Partners","Investment"],"acquisition_amount":null,"structuredIssuesShow":"#Partners  #Investment","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"G7WHsrGxSuTEs7EQw7kU9VpMAhRASiu5QM8kuNwc0fRq1RDPm1Dc0M","news_summary":"Johnson & Johnson to establish new biotechnology incubator in Israel","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"},{"id":"ed1c6ad2-27dc-4594-b240-f48b28167ac5","date":"Dec 16, 2012","link":"http://www.globes.co.il/en/article-1000806563","source":"www.globes.co.il","visible":1,"analysis":{"tags":"FDA approval","company":"Omrix","layoffs":null,"summary":"Omrix, a Johnson & Johnson unit, has obtained FDA approval for its fibrin human sealant patch, now called Evarrest. The sealant is used to stop bleeding during surgery and is 98% effective in maintaining hemostasis. Omrix will produce Evarrest in Israel. The FDA approval is good news for Johnson & Johnson and for Israels life sciences industry. Omrix is also in talks with Octapharma AG for other production options. The company is currently involved in a lawsuit with the State of Israel regarding royalties on the acquisition of intellectual property. The case is still pending.","partners":["Octapharma AG"],"customers":null,"investors":"Johnson & Johnson","confidence":9,"key_topics":["FDA approval","Evarrest","biological sealant","Johnson & Johnson","Israel"],"date_of_event":"2012-12-16","valuation_amount":null,"impact_on_company":"growth-positive","investment_amount":null,"structured_issues":["Customers"],"acquisition_amount":438000000,"structuredIssuesShow":"#Customers","entityGrowthIconPath":"url(/assets/circle-green.svg);"},"sentiment":"growth-positive","analysisId":"vHMlFBxow4qUpaTcytAtJVD3MusEzsRvqWA3VK4QHGMzFIFsSC1LTO","news_summary":"Omrix obtains FDA approval for fibrin sealant","analysisStructuredIssuesDisplay":"block","analysisImpactOnCompanyDisplay":"block"}],"extensions":[{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAgKP2oZIKDA","name":"FutuRx","type":"Investor","hidden":false,"logokey":"$XxQiFrU4R30LKDcmXaXZVedqfornovhC31j8y0EG4TthCyoN21hBrd","subtype":"Incubator","urlname":"futurx","isisraeli":1,"entitytype":"Investor","fullUrlname":"/investor_page/futurx","fundingstages":["A Round","Seed","Pre-Seed"]},{"id":"agxzfmlsbGlzdHNpdGVyGAsSC05ld19Db21wYW55GICAwITBs4MKDA","name":"Johnson & Johnson Innovation","type":"Investor","hidden":false,"logokey":"$4EccGeA7CnODtuJfuXZHm6rgAKVHb8UpRtVyqZSCmQ4mKkYeHPeURP","subtype":"Corporate VC","urlname":"johnson-johnson-development-corporation","isisraeli":0,"entitytype":"Investor","fullUrlname":"/investor_page/johnson-johnson-development-corporation","fundingstages":["B Round","E Round","G Round","C Round","A Round","Seed","F Round","D Round"]}],"events":null,"hide_reasons":[{"id":"75T5aG1f0dpqYFonup40lXNjO046zUH82TaHW1TAiIMf9aYAsSOl0d","reason":"No relevant activity"},{"id":"7KVi9S7qqUtO0WCsFclwqBEZluejfNYqWC1Uhx0tPHtDxtvxPPaCPH","reason":"No longer active"},{"id":"hoyKAmu4YJEHmhtLwCdeFldSnDwaVbPXOnH0RA9hKHCzAcHO6OOrXd","reason":"Pending approval"},{"id":"TC54H7CXyKO8GmPECkbyKJf8n34r70JlfJTJHfo85exRpLaKI1Efs9","reason":"Pending approval - External entity"}],"timeline":[{"id":"agxzfmlsbGlzdHNpdGVyFgsSCUJhc2VFdmVudBiAgOCwpqmRCAw","hub":null,"date":"1978-01-13","batch":"","token":"","amount":null,"hub_id":null,"source":"","ticker":"JNJ","enddate":"","mnatype":null,"eventtype":"POEvent","granttype":null,"valuation":null,"investment":[],"hub_logokey":null,"hub_urlname":null,"wasacquired":null,"delistreason":null,"capitalraised":null,"stockexchange":"NYSE","eventvisibility":"Public","amountvisibility":null,"duetoacquisition":null,"isextensionround":null,"token_visibility":"","fundingvisibility":null,"stockexchange_key":"agxzfmlsbGlzdHNpdGVyHAsSD0V4dGVybmFsX0VudGl0eRiAgODIgdygCww","acquiredcompany_mna":null,"communitycompany_id":null,"isjointventuregrant":null,"acquiredcompany_spac":"Undisclosed","communitycompany_name":null,"communitycompany_type":null,"stockexchange_logokey":"$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","acquiredcompany_mna_id":null,"fundingtypefundingtype":null,"acquiredcompany_reverse":null,"acquiredcompany_spac_id":null,"communitycompany_hidden":null,"communitycompany_fullurl":null,"communitycompany_logokey":null,"communitycompany_urlname":null,"acquiredcompany_reverse_id":null,"acquiredcompany_mna_logokey":null,"acquiredcompany_mna_urlname":null,"acquiredcompany_mna_homepage":null,"acquiredcompany_spac_logokey":null,"acquiredcompany_spac_homepage":null,"acquiredcompany_reverse_logokey":null,"acquiredcompany_reverse_urlname":null,"acquiredcompany_reverse_homepage":null,"hub_logourl":"/assets/empty-state.svg","stockexchange_logourl":"https://storage.googleapis.com/clean-finder-353810/$gCUzHIIl5WdaUySSBVfr4ukCJPjuwKJMFXjiY09JCLUNERZRom14T0","communitycompany_logourl":"/assets/empty-state.svg","acquiredcompany_mna_logourl":"/assets/empty-state.svg","acquiredcompany_spac_logourl":"/assets/empty-state.svg","acquiredcompany_reverse_logourl":"/assets/empty-state.svg","style":"","hiddenCompanyTooltip":""}],"techcommunityinvolvement":null,"tags":["digital-healthcare","pharmaceuticals","biopharmaceutical","therapeutics","biotechnology","supply-chain"],"investments":[],"funds":[],"databases":[],"sharedspaces":[],"utilities":[],"contributors":[],"employeesworldwide":"50,000+","fundingtype":"Multinational","parsedName":"Johnson & Johnson","logourl":"https://storage.googleapis.com/clean-finder-353810/$ZGZLV7DUlFkgUtW3RRol27Vr6RIBnPlja5TeXVQC7G3Ey1ZR0rrMIS.jpeg","oglogourl":"https://storage.googleapis.com/clean-finder-353810/$ZGZLV7DUlFkgUtW3RRol27Vr6RIBnPlja5TeXVQC7G3Ey1ZR0rrMIS.jpeg","teamMembersNumber":4,"nationality":"Foreign","communityinvolvement":[],"popup_claim_profile":"false","claimedBadge":"none","display":{"mainContact":"none"},"mainContact":{},"_eventview":{"publicoffering_exit":[],"privateequityfunding":[],"nonequityfunding":[],"merger_acquisitions":[],"others":[]}}